The groundbreaking success of the copyright undeniably transformed the drug landscape, but investing in companies heavily reliant on unbranded versions presents a uncertain picture. Although early earnings were impressive, the end of patents and the rise of discounted alternatives have weakened sales. Thus, a thorough assessment of current income s